The Catch in Precision Oncology: Why Not All Genetic Matches Are Equal
Matching cancer drugs to genetic mutations only improves survival when backed by strong clinical trial data. Borrowing treatments from other cancer types based solely on a shared mutation does not offer the same benefit.
By Lin, Thavaneswaran, Grady, Napier, Kansara, Sebastian, Kee, Desai, Zaheed, Chinchen, Oakes, Blackburn, Scott, Glover, Fox, Goldstein, Leo, Amanuel, Mersiades, Millward, Brown, Charakidis, Pokorny, Craft, Espinoza, Grimison, Harrup, Joshua, O’Byrne, Lee, Cowley, Ballinger, Simes, Thomas, Australian Molecular Screening and Therapeutic program investigators and contributors, Hughes, Itchins, Karapetis, Lane, Peters, Parakh, Ross, Sjoquist, Shackleton, Nagrial, Moore, Moore, Underhill, Barker, Collignon, Conole, Cowley, Gu, Hajdu, Heyer, Hesson, Ip, Mifsud, Pinese, O'Grady, Prawira, Qiu, Silvestri, Thornton, Walwyn, Ye, Zaratzian, Barrie, Cummins, Dheer, Harwood, Hoque, Finlayson, Lie, Marschner, Morton, Murray, Nicholas, Omotoso, Pallimulla, Pandya, Richardson, Ristevski, Thomas, Wheeler, Xie, Terry, Dobbins, Brown, McGovern, King, Schreiber, Chang, Tapia-Rico, Whelan, Humphries
